BlackRock has launched the iShares Nasdaq US Biotechnology UCITS ETF investing directly in biotech and pharmaceutical stocks which are listed on the Nasdaq stock exchange.
Listed on the London Stock Exchange on 23 October, the ETF has a total expense ratio (TER) of 0.35% and will track the Nasdaq Biotechnology index. The index, which has 161 stocks, is calculated using a modified cap-weighted methodology. The top five constituents are capped at 8% of the total index, while the remaining holdings are capped at 4%. The top five holdings are Biogen, Amgen, Celgene Corp, Gilead Sciences and Regeneron Pharmaceuticals. Does recent tech sell-off signal 'beginning of the end' for turbo-charged rally? The firm said the market's focus on aging demographics ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
